Cancer Research and Treatment

The Korean Cancer Association (대한암학회)
권호 표지

5-FU Induces Apoptosis of Fas (+), HepG2 Cells Via Activation of Fas-mediated Caspase and Mitochondria Dysfunction

Park, Chan-Ny;Yoon, Kui-Hyun;Lee, Young-Jin;Kim, Yong-Kweon;Choi, Yee-Cheon;Shin, Jae-Hoon;Cho, Jeong-Hwan;Park, Rae-Kil

  • Published : 20020000
⟨ Previous Next ⟩

Abstract

Purpose: In order to investigate the role of Fas on the chemosensitivity of cancer cells in regards to chemotherapeutic agents, the Fas/FasL signaling pathway of apoptosis was explored in human hepatoma cells. Materials and Methods: Fas expression of hepatoma cells including Chang, Huh7, HepG2, and Hep3B cells, was determined by RT-PCR and flow cytometry analysis. Cell viability was measured by MTT assay and apoptosis was assessed by DNA fragmentation assay. The catalytic activity of the caspase-family proteases including caspase-3, 6, 8, and 9 proteases, was tested using fluorogenic biosubstrates. The expression of apoptotic mediators including cytochrome c, PARP, and Bcl2 family proteins were measured from cytosolic and mitochondrial compartments. Mitochondrial membrane potential was measured by fluorescence staining with JC-1, rhodamine 123. Results: Fas mRNA was constitutively expressed in Chang and HepG2 as defined as Fas (+) cells, but not in Huh7 and Hep3B cells, defined as Fas (-) cells. Fas (+) cells were markedly sensitive to 5-FU whereas Fas (-) cells were resistant and able to survive. 5-FU increased Fas expression of Fas (+) HepG2 cells and simultaneously resulted in apoptotic death, characterized by the ladder-pattern fragmentation of genomic DNA. Moreover, it increased the catalytic activity of caspase-8 protease, which eventually cleaved the Bid into truncated Bid which translocated into mitochondria only in Fas (+) cells. It also increased the caspase-9 protease activity with Bax expression, cytosolic release of cytochrome c, and mytochondrial dysfunction only in Fas (+) HepG2 cells. Furthermore, 5-FU increased the enzymatic activity of caspase-3 protease with PARP digestion in HepG2 cells. Conclusion: 5-FU exerted cytotoxicity against hepatoma cells via activation of Fas-mediated apoptotic signaling including caspase cascades and mytochondrial dysfunction. Our data suggests that Fas may be an important modulator of the chemosensitivity of cancer cells vis- -vis anticancer chemotherapeutic agents.

Keywords

References

  1. Barry, MA, Behnke, CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990;40:2353- 2362 https://doi.org/10.1016/0006-2952(90)90733-2
  2. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death. Cell 1996; 85:803-815 https://doi.org/10.1016/S0092-8674(00)81265-9
  3. Budijardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999;15:269-290 https://doi.org/10.1146/annurev.cellbio.15.1.269
  4. Eichhorst ST, Muller M, Li-Weber M, Schulze-Bergkamen H, Angel P, Krammer PH. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol Cell Biol 2000;20:7826-7837 https://doi.org/10.1128/MCB.20.20.7826-7837.2000
  5. Eichhorst ST, Muller M, Li-Weber M, Schulze-Bergkamen H, Angel P, Krammer PH. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol Cell Biol 2000;20:7826-7837 https://doi.org/10.1128/MCB.20.20.7826-7837.2000
  6. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996:2;574-577 https://doi.org/10.1038/nm0596-574
  7. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997;57:3823-3829
  8. Gross A, McDonnell JM, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 1999;13:1899- 1911 https://doi.org/10.1101/gad.13.15.1899
  9. Rhee HW, Kang SH, Hwang TK, Leland WK Chung. Permanent genotypic and phenotypic change of prostate cancer cell line LNCaP through cellular interactions with prostate or bone fibroblasts in vitro or in vivo. J Korean Cancer Assoc 2001;33(2):168-177
  10. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME. Cytotoxicity-dependent APO-1 (Fas/ CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO 1995;14:5579-5588
  11. Koichi S, Teruhisa K, Masayuki Y, Takeji U, Toshihiko K, Taizo K, Teruhiko Y, Haruhiko S. Drug-induced Apoptosis and p53, Bcl-2 and Bax expression in breast cancer tissue in vivo and fibroblast cells in vitro. JJCO 2002;29:7:323-331 https://doi.org/10.1093/jjco/29.7.323
  12. LiPF, Dietz R, Von Harsdorf R. 53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO 1999;18:6027-6036 https://doi.org/10.1093/emboj/18.21.6027
  13. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin KM. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 1997;90:3118-3129
  14. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR. Druginduced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997;99:403-413 https://doi.org/10.1172/JCI119174
  15. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li- Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH. Related articles, nucleotide p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998;188:2033-2045 https://doi.org/10.1084/jem.188.11.2033
  16. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-827 https://doi.org/10.1016/S0092-8674(00)81266-0
  17. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME. Apoptosis signaling by death receptors. Eur J Biochem 1998; 254:439-459 https://doi.org/10.1046/j.1432-1327.1998.2540439.x
  18. Searle J, Kerr JF, Bishop CJ. Necrosis and apoptosis: distinct modes of cell death with fundamentally different significance. Pathol Annu 1982;17:229-259
  19. Trauth BC, Klas C, Peters AMJ, Matzuku S, Moller P, Falk W, Debatin KM, Krammer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245: 301-305 https://doi.org/10.1126/science.2787530
  20. Vander Heiden MG, Chandel NS, Williamson EK, Schumacker PT, Thompson CB. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell 1997;91:627- 637 https://doi.org/10.1016/S0092-8674(00)80450-X
  21. Vander Heiden MG, Thompson CB. Bcl-2 proteins: inhibitors of apoptosis or regulators of mitochondrial homeostasis? Nat Cell Biol 1999;1:E209-E216 https://doi.org/10.1038/70237
  22. Wesselborg S, Engels IH, Rossmann E, Los M, Schulze- Osthoff K. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood 1999;93:3053-3063
  23. Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Rothe KA, Korsmeyer SJ. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999;400:886-891 https://doi.org/10.1038/23730
  24. Zhang JK, Cado D, Chen A, Kabra NH, Winoto A. Fasmediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 1998; 392:296-300 https://doi.org/10.1038/32681